{
  "id": 7114683,
  "title": "Lupin to bet big on biosimilar sales in mid term, ramp capacity expansion",
  "url": "https://urgent.news/2026/09/13/lupin-to-bet-big-on-biosimilar-sales-in-mid-term-ramp-capacity",
  "topic": "business",
  "section": "Business",
  "published": "2026-09-13T11:58:14.000Z",
  "source": {
    "name": "Business Standard IN",
    "slug": "business-standard-in",
    "url": "https://www.business-standard.com/industry/news/companies-news-lupin-eyes-500-mn-biosimilars-revenue-in-medium-term-126091300205_1.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "The company plans to soon start the funding process for its oncology spin-off, Kaveri Therapeutics, which houses two specialised oncology programmes",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}